<SEC-DOCUMENT>0001683168-19-003867.txt : 20191203
<SEC-HEADER>0001683168-19-003867.hdr.sgml : 20191203
<ACCEPTANCE-DATETIME>20191203090011
ACCESSION NUMBER:		0001683168-19-003867
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191203
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191203
DATE AS OF CHANGE:		20191203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700]
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19621
		FILM NUMBER:		191264717

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>janone_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>December 3, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>JanOne
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-19621</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>41-1454591</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>325 E. Warm Springs Road, Suite 102, Las Vegas, NV</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>89119</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(702) 997-5968</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&#9744;</TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">JAN</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC<BR>
(Nasdaq Capital Market)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect; 240.12b 2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 8.01.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December
3, 2019, JanOne Inc. issued a press release announcing the appointment of Tony Giordano, Ph.D., as its Chief
Scientific Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 96px; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial
Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt"><B>(d)</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>Exhibit No.</B></P></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><A HREF="janone_8k-ex9901.htm">Press Release issued by JanOne Inc. on December 3, 2019.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 50%"><FONT STYLE="font-size: 10pt"><B>JanOne Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: December 3, 2019</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><U>/s/ Tony Isaac&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tony Isaac</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>janone_8k-ex9901.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FOR IMMEDIATE RELEASE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact: Michele Hart Henry; 1-302-463-6167</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>JanOne
Names Tony Giordano, Ph.D., as Chief Scientific Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Giordano to lead all development initiatives
for JanOne&rsquo;s clinical candidates, including its recent acquisition of TV1001SR to treat PAD and associated pain</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Las Vegas, Nevada, December 3, 2019 </B>&ndash; JanOne Inc.
(NASDAQ:JAN) a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing
to market drugs and therapies with nonaddictive pain-relieving properties, announced the hiring of Tony Giordano, Ph.D. to serve
as its Chief Scientific Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Giordano is&nbsp;JanOne&rsquo;s new Chief Scientific Officer
and founding scientist. As Chief Scientific Officer, Dr. Giordano will oversee development of the company&rsquo;s recently announced
PAD treatment, TV1001SR including the phase 2b clinical protocol, manufacturing, and phase 2b clinical trials. In addition to his
role with JanOne, he also serves as Senior Director of Special Projects in the Innovations Center at the Cleveland Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I&rsquo;m delighted to announce Dr. Giordano&rsquo;s
appointment as Chief Scientific Officer,&rdquo; said&nbsp;Eric Bolling, president of JanOne. &ldquo;His knowledge and his experience
in the sciences are invaluable in helping create and advance JanOne&rsquo;s mission. We look forward to his leadership as we work
to develop JanOne&rsquo;s pipeline of drug treatments to target the cause of pain, or pain itself, and that in the future may replace
opioids currently in medicine cabinets across America.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Dr. Giordano will play a key role in the identification
of future clinical candidates as we develop our pipeline, targeting solutions that can treat an underlying condition and associated
pain without the need for opioids, &ldquo; said Tony Isaac, JanOne&rsquo;s Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As an experienced researcher and bioscientist, Dr. Giordano&nbsp;has
held senior positions at cutting-edge biotechnology companies. As President of Sulfagenix, Inc., he managed the&nbsp;completion
of a Phase 1 clinical study, GRAS affirmation and launch of medical food product.&nbsp;&#8203;As Chief Executive Officer of Theravasc,
Inc., he managed collaborations and development of a new drug formulation, TV1001SR, that JanOne recently licensed, and oversaw
and managed the Phase 1 clinical study and two-Phase 2 studies. He also held senior positions at&nbsp;Message Pharmaceuticals,
Inc., Nucleonics, Inc., and Alteris, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am honored to be named JanOne&rsquo;s Chief
Scientific Officer,&rdquo; said Dr. Giordano. &ldquo;I am fortunate to have the opportunity to continue my work with TV1001SR
and to advance it into Phase 2b for treating PAD with an additional indication for PAD-associated pain. The potential down
the road to explore how TV1001SR may provide non-addictive pain relief to patients with various chronic pain conditions will shape
our future research.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to Theravasc, Dr. Giordano had served as an Adjunct Professor
of Biology at Case Western University, Special Advisor to the Chancellor at LSU Health Sciences Shreveport and as the Assistant
Dean of Research and Business Development at Louisiana State University&rsquo;s Health &amp; Sciences Center, where he worked with
faculty to define the commercial potential of their research and identified and brought in funding through sponsored research agreements.
Additionally, Dr. Giordano served as Director of Experimental Therapeutics in the Feist-Weiller Cancer Center, and as&nbsp;Associate
Professor in the Departments of Pharmacology and Biochemistry.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">He served as&nbsp;advisor to three biotechnology venture capital&nbsp;funds,
a consultant to the Biomedical Research Foundation, and was appointed by the Governor of Louisiana to the Innovation Council. Dr.
Giordano&nbsp;has more than 20 issued patents and a number of pending patent applications and has published more than 50 research
studies. Before beginning his career in biotech, Dr. Giordano was a senior scientist at Abbott Laboratories. Dr. Giordano&nbsp;earned
a Ph.D. in Molecular Genetics at Ohio State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I&rsquo;m looking forward to the potential of building
a leading drug discovery and development platform in the non-opioid pain space and pipeline of treatments that may someday positively
affect the lives of millions of people across the globe,&rdquo; Dr. Giordano continued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About JanOne </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JanOne is a unique NASDAQ-listed company offering innovative,
actionable solutions that it believes can help create an end to the opioid crisis. JanOne is dedicated to funding resources toward
innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and
widespread in the country's history. The company continues to operate its legacy businesses &ndash; ARCA Recycling and GeoTraq
&ndash; under their current brand names. JanOne's subsidiary ARCA Recycling recycles household appliances by providing turnkey
recycling and replacement services for utilities and other sponsors of energy efficiency programs. JanOne's subsidiary GeoTraq
engages in the development, design and, ultimately, expected sale of Mobile IoT modules. Please visit www.janone.com for additional
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>###</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  L +<# 2(  A$! Q$!_\0
M'    @(# 0$               8%!P,$" $"_\0 /!   0,# 04%! @$!P
M     0(#!  %$08'$A,A,4%187&1(G*!L0@R-#=SH;+1%1<S-B-"4G2"L\'_
MQ  : 0 " P$!               #! (%!@$ _\0 -!$  0,"! ,&!0('
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M*/%>S \H-.S+B7F4.(^JM(4/(T5C@,&+"884K>+: @JQUP**VJ"2D%6]9U4
MF-JU[Y#>GVYR/'>#2E\B2.H[JK6<Q-M)6@P;M*4#R:BL*W5_\NF/7RJV:*K[
MO"F+MP.N3(TW-/6E^JV&6)%4%9MG-]U3J-=SU+'_ (?"6L*4T3[92, (2.P8
M &35[+B,+A&&II)C%OA%O'+=QC'I6>BG6F4M"$U/$,4>OU)*] G8#85S=K#9
M;?+-<EO65AV=!WMYI;/-QON!'7([Q6:T:0UOJA3<:\OW"/;4<U*EN*Z#L2@G
MF?RKHNBA?"(F9TJU_55T6PE24E0V41KX])KGO9OH?45JUQ:YLZUNLQ6EJ*W%
M*3@ H4!T/B*:MN.F;QJ"5:E6>"Y*2RAP+*2!NDD8ZGPJVJ*D+=(043H:6<_B
M%]R\1>E(S)$1K'/O[Z5-EMMF6C1%OA7%A3$ILN;S:B"1E:B.G@:4=N6F;QJ"
M3:%6>"Y*2RAT.%) W<E..I\#5LT5-304C)RI-C%'&+PWJ0,Q),<M9]Z4=E%K
MF6?1$*%<F%,2FU.%3:B"1E9(Z>!J1U'IYJ[#BMJ#4H# 5CDH=Q_>IVBH/6K3
M[7!=$B@+O'%7"KD:*42?.JO=L-WA.'=8<]YHY!]*&K#=YK@WV'??=. /6K0H
MJB_3%O/SJCII[4Y_.78^434%IS3S5I'%<(=E*&"K')([A^];&J8STNR/LQD%
MQU13A(]X5*T5<BQ91;FV;$)((\_O5>;EQ3H>49(I3T1;)EO=EF8PIH+2G=R1
MSZU+ZGC/2[*^S'05NJ*<)'F*E:*@SA[;5J;0$Y2"._6I.72EO<<C73TI3T1;
M)EO>E&8PIH+2D))(Y\S6SJG3HNF)$8A$I(P0>BQ^],=%01A3 M?A%:I[]^M2
M5>N%[CC0U6S+&HK>."RF4A/<D;P^'45)6&U7I5T;FRW%-;I]HNJR5#M&*=Z*
A39P%MM227%$)U G3\\J8<Q-2TD! !.YBBBBBKZJRO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A (T# 2(  A$! Q$!_\0
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M)3E5Y)1>WO.]SFQ51N*AS)^BL+1117K'"%%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
